Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 5/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19219760 | 0.91 | KMT2A (0.41) | TRIM24KMT2APKMLMNAMEN1 | |
| SCHEMBL17545074 | 0.85 | KMT2A (0.52) | TRIM24NOTUMKMT2APKMLMNA | |
| SCHEMBL17545073 | 0.83 | CYP11B2 (0.52) | TRIM24NOTUMKMT2APKMLMNA | |
| SCHEMBL17545288 | 0.80 | LMNA (0.50) | TRIM24NOTUMKMT2APKMLMNA | |
| SCHEMBL15882573 | 0.78 | NOTUM (0.51) | TRIM24NOTUMKMT2APKMLMNA | |
| SCHEMBL29707960 | 0.78 | NOTUM (0.51) | TRIM24NOTUMKMT2APKMLMNA | |
| SCHEMBL17545149 | 0.77 | USP2 (0.53) | TRIM24KMT2APKMLMNACYP11B2 | |
| SCHEMBL19219758 | 0.76 | KDM4E (0.46) | TRIM24KMT2APKMLMNAMEN1 | |
| SCHEMBL23613816 | 0.75 | KMT2A (0.48) | TRIM24NOTUMKMT2APKMLMNA | |
| SCHEMBL15882287 | 0.74 | NOTUM (0.55) | TRIM24NOTUMKMT2APKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180312-B1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | UNIV LOYOLA CHICAGO (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10385040-B2 | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same | LOYOLA UNIVERSITY OF CHICAGO (US) | 2019-08-20 | — | — | US | disclosed |
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-08-10 | — | — | US | disclosed |
| WO-2016025637-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | LOYOLA UNIVERSITY OF CHICAGO (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385040-B2 | Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same | INMT, MGAM, NNMT | TRIM24 1559/4885NOTUM 581/4885KMT2A 1720/4885 |
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | INMT, MGAM, NNMT | TRIM24 1559/4885NOTUM 581/4885KMT2A 1720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.